Bio-tech diagnostic company Pulmatrix has taken its funding past the $60m with a round backed by the Switzerland-based pharmaceutical company Novartis, among others.
US-based biopharmaceutical company Pulmatrix has secured an initial $14m in additional series B funding from existing investors, including Novartis Venture Funds, the corporate venturing unit belonging to the eponymous pharmaceutical company.
Novartis Bioventures Fund had previously co-led Pulmatrix’s initial series B round, in November 2009, which raised $30.2m. Also participating in both rounds were US-based venture capital (VC) firms Arch Venture Partners, Polaris Venture Partners and 5am Ventures.
Filings with the US Securities and Exchanges Commission showed Pulmatrix had received…
